| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/13/264:02 PM | -$2.38 | -$2.46GAAP | -3.4% | -8% | — | $0 | — | — | |
| Q2 '26 | 8/13/264:04 PM | -$2.32 | -$2.34GAAP | -0.9% | -26% | — | $0 | — | ⚠ Check | |
| Q1 '26 | 5/14/264:05 PM | -$1.43 | -$2.15GAAP | -50.3% | +23% | — | $0 | — | — | |
| Q4 '25 | 3/19/264:00 PM | -$2.45 | -$2.11GAAP | +13.9% | +32% | — | $0 | — | ⚠ Check | |
| Q3 '25 | 11/14/256:00 AM | -$2.21 | -$2.28GAAP | -3.2% | +20% | — | $0 | — | — | |
| Q2 '25 | 8/13/254:05 PM | -$2.73 | -$1.85GAAP | +32.2% | -101% | — | $1.30M | — | ⚠ Check | |
| Q1 '25 | 5/14/254:05 PM | -$3.45 | -$2.80GAAP | +18.8% | +51% | — | $0 | — | — |
⚠ Potential error in calculation, check manually. Reported revenue shows as zero, which usually means the figure is missing. The two revenue figures may be in different units or currencies.
GAAP = diluted EPS as filed with the SEC.